Compr Physiol (2017) 81:299314
In the United Kingdom, they are approved for weight management when combined with a reduced calorie diet and physical activity for people with obesity or for those who are overweight with related health issues
Clinical trials demonstrated an average weight loss of 12.4%, making it a beneficial option for those needing a more adaptable regimen
at this dose, tirzeaptide drives ~8.3% weight loss compared to 6.6% for semaglutide over 40 weeks in the head-to-head SURPASS-2 trial in patients with obesity and T2D
Importantly, Zepbound carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Common side effects include frequent urination, urinary tract and genital yeast infections, increased thirst, nausea, joint pain, upper respiratory infections, increased cholesterol, and weight loss
)
